Tirofiban vs. Aspirin to Reduce Early Neurologic Deterioration After Acute Ischemic Stroke

Tirofiban reduced END compared with aspirin, but this did not translate into significant improvement in early NIHSS scores or 90-day functional outcomes.

Oral antiplatelet therapy has been the mainstay of treatment for acute ischemic stroke. Recent trials have evaluated the use of tirofiban, an intravenous glycoprotein IIb/IIIa receptor inhibitor with resultant antiplatelet activity, beyond its current FDA-approved indication for acute coronary disease, to include acute ischemic stroke. In the open-label, blinded-endpoint TREND trial, 425 patients with acute noncardioembolic stroke presenting to 10 centers in China within 24 hours of symptom onset were randomized to receive either intravenous tirofiban or oral aspirin alone for 72 hours; both groups received aspirin monotherapy. Enrolled patients (29% female) were aged 18 to 80 and had an initial NIH Stroke Scale (NIHSS) score between 4 and …

Reviewing Author

Anthony S. Kim, MD

Disclosures

Grant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences

Anthony S. Kim, MD

Disclosures

Grant/Research SupportNIH/National Institute of Neurological Disorders and Stroke; NIH/National Center for Advancing Translational Sciences

Tirofiban vs. Aspirin to Reduce Early Neurologic Deterioration After Acute Ischemic Stroke

Topics

Reviewing Author